Aquaretic Effect of Lixivaptan, an Oral, Non-Peptide, Selective V2 Receptor Vasopressin Antagonist, in New York Heart Association Functional Class II and III Chronic Heart Failure Patients

Aim. Еvaluate the influence of combination therapy with fosinopril or zofenopril on the regulatory-adaptive status (RAS) of patients with diastolic chronic heart failure (CHF). Material and methods. The study includes 80 patients with CHF I-II functional class according to the classification of the New York heart Association with left ventricle ejection fraction ≥50% because of hypertensive disease (HD) of III stage, who were randomized into two groups for treatment with fosinopril (14.7±4.2 mg/day, n=40) or zofenopril (22.5±7.5 mg/day, n=40). As part of combination pharmacotherapy, patients were included nebivolol (7.1±2.0 mg/day and 6.8±1.9 mg/day), in the presence of indications, atorvastatin and acetylsalicylic acid in the intestinal shell were prescribed. Initially and after six months, the following was done: a quantitative evaluation of the RAS (by cardio-respiratory synchronism test), echocardiography, tredmil-test, six-minute walking test, determination of the N-terminal precursor of the natriuretic brain peptide level in blood plasma and subjective evaluation of quality of life. Results. Therapy, using fosinopril, in comparison with zofenopril, more improved RAS (by 66.5%, p

Download Full-text

Type D personality is a predictor of poor emotional quality of life in primary care heart failure patients independent of depressive symptoms and New York Heart Association functional class

Journal of Behavioral Medicine ◽

10.1007/s10865-009-9236-1 ◽

2009 ◽

Vol 33 (1) ◽

pp. 72-80 ◽

Cited By ~ 31

Author(s):

Susanne S. Pedersen ◽

Christoph Herrmann-Lingen ◽

Peter de Jonge ◽

Martin Scherer

Keyword(s):

Quality Of Life ◽

Heart Failure ◽

New York ◽

Heart Association ◽

Functional Class ◽

Emotional Quality ◽

Heart Failure Patients ◽

Type D ◽

New York Heart Association

Download Full-text

Agreement between heart failure patients and providers in assessing New York Heart Association functional class

Heart & Lung ◽

10.1016/j.hrtlng.2017.05.001 ◽

2017 ◽

Vol 46 (4) ◽

pp. 293-299 ◽

Cited By ~ 8

Author(s):

Brent A. Williams ◽

Sanjay Doddamani ◽

Melissa A. Troup ◽

Alison L. Mowery ◽

Cynthia M. Kline ◽

...

Keyword(s):

Heart Failure ◽

New York ◽

Heart Association ◽

Functional Class ◽

Heart Failure Patients ◽

New York Heart Association

Download Full-text

Outpatient Costs of Medications for Patients with Chronic Heart Failure

American Journal of Critical Care ◽

10.4037/ajcc2002.11.5.474 ◽

2002 ◽

Vol 11 (5) ◽

pp. 474-478 ◽

Cited By ~ 15

Author(s):

Leslie C. Hussey ◽

Sonya Hardin ◽

Christopher Blanchette

Keyword(s):

Heart Failure ◽

New York ◽

Chronic Heart Failure ◽

Web Sites ◽

Heart Association ◽

Class Ii ◽

Class I ◽

Class Iii ◽

Ability To Pay ◽

New York Heart Association

• Background The outpatient costs of medications prescribed for chronic heart failure are high and are often borne by individual patients. Lack of financial resources may force noncompliance with use of medications. • Objective To compare the outpatient costs of medications for patients with different New York Heart Association classifications of chronic heart failure. • Methods The charts of 138 patients with chronic heart failure were reviewed retrospectively. Outpatient costs of medications were obtained from the Web sites of commercial pharmacies. Medications were classified by type according to the system of the American Heart Association. A mean cost for each classification of medication was used for analysis. • Results The overall mean monthly cost of medications for chronic heart failure was $438. Patients with class II and class III chronic heart failure had the highest costs: $541 and $514, respectively. Analysis of variance indicated that the differences in monthly costs of medications between the patients with the 4 stages of chronic heart failure were significant (F = 4.86, P = .003). A post hoc Scheffé test revealed significant differences in costs between patients with class I and patients with class II heart failure (P=.02) and between patients with class I and those with class III heart failure (P=.02). • Conclusions The outpatient costs of medications for chronic heart failure are significant. Ability to pay for prescribed medications must be determined. Healthcare professionals must maintain an awareness of the costs of medications and patients’ ability to pay.

Download Full-text

Estimating New York Heart Association Classification for Heart Failure Patients from Information in the Electronic Health Record

2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) ◽

10.1109/bibm.2018.8621518 ◽

2018 ◽

Cited By ~ 1

Author(s):

Sisi Ma ◽

Rui Zhang ◽

Jessica Munroe ◽

Lindsey Shanahan ◽

Sarah Horn ◽

...

Keyword(s):

Heart Failure ◽

New York ◽

Electronic Health Record ◽

Heart Association ◽

Health Record ◽

Heart Failure Patients ◽

New York Heart Association ◽

Electronic Health

Download Full-text

Remote monitoring of chronic heart failure patients: invasive versus non-invasive tools for optimising patient management

Netherlands Heart Journal ◽

10.1007/s12471-019-01342-8 ◽

2019 ◽

Vol 28 (1) ◽

pp. 3-13 ◽

Cited By ~ 5

Author(s):

J. F. Veenis ◽

J. J. Brugts

Keyword(s):

Heart Failure ◽

New York ◽

Chronic Heart Failure ◽

Remote Monitoring ◽

Heart Association ◽

The United States ◽

Pharmacological Therapy ◽

Functional Class ◽

Class Iii ◽

Additional Tool

AbstractExacerbations of chronic heart failure (HF) with the necessity for hospitalisation impact hospital resources significantly. Despite all of the achievements in medical management and non-pharmacological therapy that improve the outcome in HF, new strategies are needed to prevent HF-related hospitalisations by keeping stable HF patients out of the hospital and focusing resources on unstable HF patients. Remote monitoring of these patients could provide the physicians with an additional tool to intervene adequately and promptly. Results of telemonitoring to date are inconsistent, especially those of telemonitoring with traditional non-haemodynamic parameters. Recently, the CardioMEMS device (Abbott Inc., Atlanta, GA, USA), an implantable haemodynamic remote monitoring sensor, has shown promising results in preventing HF-related hospitalisations in chronic HF patients hospitalised in the previous year and in New York Heart Association functional class III in the United States. This review provides an overview of the available evidence on remote monitoring in chronic HF patients and future perspectives for the efficacy and cost-effectiveness of these strategies.

Download Full-text

Abstract 2848: Medication Knowledge And Assistance In Older Chronic Heart Failure Patients.

Circulation ◽

10.1161/circ.116.suppl_16.ii_633-d ◽

2007 ◽

Vol 116 (suppl_16) ◽

Author(s):

Robyn Gallagher ◽

Judith Donoghue ◽

Lynn Chenoweth ◽

Jane Stein-Parbury

Keyword(s):

Heart Failure ◽

New York ◽

Chronic Heart Failure ◽

Self Efficacy ◽

Heart Association ◽

Post Discharge ◽

Medication Knowledge ◽

Moderate Heart Failure ◽

Association Class ◽

New York Heart Association

Medication knowledge and assistance in older chronic heart failure (CHF) patients. Medication adherence is central to the optimal management of CHF. Little is known about older patients’ knowledge of their medications or the factors that contribute to this knowledge. Aim: To describe and identify the predictors of medication knowledge in older CHF patients. Method: Subjects ( n = 62) aged over 55 years with moderate heart failure (New York Heart Association Class II and III) who identified as self-managing were recruited from hospital or rehabilitation. Interviews occurred at home four weeks post-discharge using a medication checklist and the Self-Efficacy in Chronic Illness Scale (Lorig et al, 2001). Multiple regression analysis determined the predictors of medication knowledge. Results: Patients were aged mean 78.4 years (sd 8.54 years), mostly male (57%) and had an average 8 (median, range 3–22) medications to take daily, of which 6 (median, range 3–14) were for CHF. Most managed their own medications (54%) but more than a quarter (28%) were assisted by reminding, dispensing and supervision. Compliance with medications was high (84%), although only half (53%) knew the name, main purpose and side effect of their medications. Patients with better self-efficacy (β = 2.88) and no help with medication (β = -21.05) had better medication knowledge (model F = 13.6, p = .000, R = .61, r 2 = .37). Conclusion: Older CHF patients have poor knowledge of their medications, which may be improved by promoting overall self-efficacy for disease management. Less knowledgeable patients received appropriate assistance with medications, but the consequence may be less knowledge and thus warrants further investigation.

Download Full-text